The IDIBELL Neurometabolic Diseases team, which is also part of CIBERER, plans to start the study in early 2022 with the anti-inflammatory dimethyl fumarate in patients with this condition. The study...
Read moreRadiomics and OncoDNA are pleased to announce that they have entered into a strategic agreement, combining Radiomics’ next-generation AI-based technology to extract quantitative information embedded...
Read moreThe Phase II trial studied the safety, tolerability, and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care Mesalazi...
Read moreThe clinical trials will be conducted in two centers in India: the All India Institute Of Medical Sciences (AIIMS) of New Delhi, and the Agartala Government Medical College of Agartala
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...
Read moreThe ACROPOLI clinical trial is being launched. It is a pioneering, nationwide research study that aims to assess the efficacy of immunotherapy in 29 different types of cancer simultaneously.
Read moreFriedreich's ataxia is a minority neurodegenerative disease characterised by difficulty in coordinating movements
Read moreThe biopharmaceutical company Ability Pharmaceuticals, SL today announced the inclusion of the first patients in a phase 2b clinical trial with its novel autophagy-inducer anticancer compound ABTL0812...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the p...
Read more